Skip to main content

Table 1 Patient demographics, tumor characteristics and treatment modalities

From: Dose-volume relationship for laryngeal substructures and aspiration in patients with locally advanced head-and-neck cancer

  All Patients (n = 29) Aspirators (n = 10) Non-aspirators (n = 19) p-value
Median age 54 (30–73) 54 (31–67) 54 (30–73) 0.75
Dose (cGy) 7000 (6400–7500) 7175 (7000–7500) 7000 (6400–7500) 0.11
  N (%) N (%) N (%)  
Sex
 Male 23 (79.3) 7 (70.0) 16 (84.2) 0.63
 Female 6 (20.7) 3 (30.0) 3 (15.8)  
Smoking
 No 23 (79.3) 6 (60.0) 17 (89.5) 0.14
 Yes 6 (20.7) 4 (40.0) 2 (10.5)  
Tumor Site
 Oropharynx 22 (75.9) 9 (90.0) 13 (68.4) 0.065
 Unknown Primary 6 (20.7) 0 6 (31.6)  
 Hypopharynx 1 (3.5) 1 (10.0) 0  
T stage
 T0 5 (17.2) 0 5 (26.3) 0.18
 T1 8 (27.6) 3 (30.0) 5 (26.3)  
 T2 11 (37.9) 4 (40.0) 7 (36.8)  
 T3 4 (13.8) 3 (30.0) 1 (5.3)  
 T4 1 (3.5) 0 1 (5.3)  
N stage
 N1 1 (3.5) 0 1 (5.3) 0.17
 N2a 3 (10.3) 0 3 (15.8)  
 N2b 21 (72.4) 7 (70.0) 14 (73.7)  
 N2c 4 (13.8) 3 (30.0) 1 (5.3)  
Stage
 III 2 (6.9) 1 (10.0) 1 (5.3) 0.42
 IVA 26 (89.6) 8 (80.0) 18 (94.7)  
 IVB 1 (3.5) 1 (10.0) 0  
Grade
 1 1 (3.5) 0 1 (5.3) 0.44
 2 9 (31.0) 5 (50.0) 4 (21.1)  
 3 9 (31.0) 2 (20.0) 7 (36.8)  
 Unknown 10 (34.5) 3 (30.0) 7 (36.8)  
p16 status
 Positive 14 (48.3) 3 (30.0) 11 (57.9) 0.99
 Negative 1 (3.4) 0 1 (5.3)  
 Unknown 14 (48.3) 7 (70.0) 7 (36.8)